Nautilus Biotechnology, Inc. (NAUT) intrinsic value & 10-year financials
Nautilus Biotechnology, Inc. (NAUT) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.06
- Market cap
- $260.1M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -18.9%
- Free cash flow (FY2025)
- -$52.0M
NAUT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$59.0M | -$0.47 | -$52.0M | — | -31.2% |
| FY2024 | — | -$70.8M | -$0.56 | -$61.3M | — | -29.2% |
| FY2023 | — | -$63.7M | -$0.51 | -$54.2M | — | -25.2% |
| FY2022 | — | -$57.9M | -$0.46 | -$48.1M | — | -26.6% |
| FY2021 | — | -$50.3M | -$0.60 | -$41.5M | — | -56.3% |
| FY2020 | — | -$15.6M | -$0.18 | -$14.9M | — | 55.2% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Nautilus Biotechnology, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Nautilus Biotechnology, Inc. has historically struggled to out-earn its cost of capital, averaging just -18.9% ROIC.
Nautilus Biotechnology, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Nautilus Biotechnology, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.